

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Contents lists available at ScienceDirect

Clinical Microbiology and Infection



journal homepage: www.clinicalmicrobiologyandinfection.com

Letter to the Editor

Predictors and microbiology of respiratory and bloodstream bacterial infection in patients with COVID-1: author's response

Bradley J. Langford ^{1, 2, *}, Miranda So ^{3, 4, 5}, Valerie Leung ^{1, 6}, Sumit Raybardhan ⁷, Jennifer Lo ⁸, Tiffany Kan ⁶, Felicia Leung ⁴, Nick Daneman ^{1, 9, 10, 13, 14}, Derek R. MacFadden ¹¹, Jean-Paul R. Soucy ¹²

¹⁾ Health Protection, Public Health Ontario, Toronto, Ontario, Canada

³⁾ Sinai Health-University Health Network Antimicrobial Stewardship Program, University Health Network, Toronto, Ontario, Canada

- ⁸⁾ Pharmacy Department, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
- 9) Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada

¹⁰⁾ Sunnybrook Research Institute, Toronto, Ontario, Canada

- ¹³⁾ Division of Infectious Diseases, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
- ¹⁴⁾ Institute of Health Policy, Management and Evaluation, University of Toronto, Ontario, Canada

ARTICLE INFO

Article history: Received 21 January 2022 Accepted 22 January 2022 Available online 4 February 2022

Editor: L. Leibovici

To the Editor,

We thank the authors for their interest and comments regarding our publication [1]. Given the vast amount of literature published on the topic of coinfections and secondary infections with coronavirus disease 2019, as well as the heterogeneity in publication quality, methodological approach, and data reporting strategies, it was necessary to make some assumptions regarding whether studies met the inclusion criteria. We agree there are certainly limitations that may affect the precision of our estimate and have highlighted some of these concerns in our discussion. Nevertheless, each of the 171 studies was reviewed by a minimum of two authors to determine if the inclusion criteria were met. However, the inclusion of some studies may still be debatable.

https://doi.org/10.1016/j.cmi.2022.01.020

Although serological testing was an exclusion criterion, certain studies did not specify the microbiological method of testing [2] and did not explicitly indicate that serological testing was used (e.g. studies may have used PCR or serology to detect *Mycoplasma* spp.); hence, these studies were included. We also made the decision to include studies of patients with ventilator-associated pneumonia (without further microbiological detail) because the vast majority of cases are caused by bacteria [3,4].

Our meta-analysis and regression specifically focused on concomitant infection caused by bacteria, so all studies counted towards an estimate of bacterial coinfection or bacterial secondary infection. Please note that the final two columns in Table S1 indicate *bacterial* coinfection and *bacterial secondary* infection. We hope this helps clarify.

Our exclusion of letters to the editor was meant to remove any commentary or narrative-type correspondence. However, we did include research letters that provided sufficient data to meet the inclusion criteria [5,6].

Given some of these limitations mentioned, we have updated the inclusion criteria in our living review so that our next update will be more stringent with respect to study inclusion (e.g. requiring an explicit statement of microbiological testing approach, exclusion of any type of letter/correspondence) [7]. The full search strategy for our most recent rapid review is now included in the supplementary material.

²⁾ Hotel Dieu Shaver Health and Rehabilitation Centre, Pharmacy Department, St. Catharines, Ontario, Canada

⁴⁾ Leslie Dan Faculty of Pharmacy, University of Toronto, Ontario, Canada

⁵⁾ Toronto General Hospital Research Institute, Toronto, Ontario, Canada

⁶⁾ Toronto East Health Network, Pharmacy Department, Michael Garron Hospital, Toronto, Ontario, Canada

⁷⁾ North York General Hospital, Pharmacy Department, North York, Ontario, Canada

¹¹⁾ ICES (formerly Institute for Clinical Evaluative Sciences), Toronto, Ontario, Canada

¹²⁾ Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

DOI of original article: https://doi.org/10.1016/j.cmi.2022.01.012.

^{*} Corresponding author. Bradley J. Langford, Public Health Ontario, Toronto, Ontario, Canada.

E-mail address: brad.langford@gmail.com (B.J. Langford).

Transparency declaration

The authors have no relevant conflicts of interest to declare. No external funding was received for this project.

Author contributions

Writing—original draft BJL; writing—review and editing: MS, VL, SR, JL, TK, FL, ND, DRM, JPS.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.cmi.2022.01.020.

References

 Langford BJ, So M, Leung V, Raybardhan S, Lo J, Kan T, et al. Predictors and microbiology of respiratory and bloodstream bacterial infection in patients with COVID-19: living rapid review update and meta-regression. Clin Microbiol Infect 2022;28:888–9.

- [2] Chen T, Dai Z, Mo P, Li X, Ma Z, Song S, et al. Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China: a single-centered, retrospective study. J Gerontol A Biol Sci Med Sci 2020;75:1788–95.
- [3] Luyt CE, Hékimian G, Koulenti D, Chastre J. Microbial cause of ICU-acquired pneumonia: hospital-acquired pneumonia versus ventilator-associated pneumonia. Curr Opin Crit Care 2018;24:332–8.
- [4] Kalanuria AA, Mirski M, Ziai W. Ventilator-associated pneumonia in the ICU. In: Vincent JL, editor. Annual update in intensive care and emergency medicine. New York City, NY: Springer International Publishing; 2014. p. 65–77.
- [5] Lee S, Koh JS, Kim YJ, Kang DH, Park D, Park HS, et al. Secondary infection among hospitalized COVID-19 patients: a retrospective cohort study in a tertiary care setting. Respirology 2021;26:277–8.
- [6] Elabbadi A, Turpin M, Gerotziafas GT, Teulier M, Voiriot G, Fartoukh M. Bacterial coinfection in critically ill COVID-19 patients with severe pneumonia. Infection 2021;49:559–62.
- [7] Langford BJ, So M, Leung V, Simeonova M, Lo J, Raybardhan S, et al. Antibiotic resistant infections in patients with COVID-19: a rapid review. Prospero 2021. CRD42021297344.